Cargando…
Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital
Hepatitis C virus (HCV) chronic infection is a major causative factor for several chronic liver diseases, including liver cirrhosis, liver cell failure, and hepatocellular carcinoma. The HCV has seven major genotypes. Genotype 4 is the most prevalent genotype in the Middle East, including Saudi Arab...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967136/ https://www.ncbi.nlm.nih.gov/pubmed/36828508 http://dx.doi.org/10.3390/tropicalmed8020092 |
_version_ | 1784897189949997056 |
---|---|
author | Hawsawi, Nahed Mohammed Saber, Tamer Salama, Hussein M. Fouad, Walaa S. Hagag, Howaida M. Alhuthali, Hayaa M. Eed, Emad M. Saber, Taisir Ismail, Khadiga A. Al Qurashi, Hesham H. Altowairqi, Samir Samaha, Mohmmad El-Hossary, Dalia |
author_facet | Hawsawi, Nahed Mohammed Saber, Tamer Salama, Hussein M. Fouad, Walaa S. Hagag, Howaida M. Alhuthali, Hayaa M. Eed, Emad M. Saber, Taisir Ismail, Khadiga A. Al Qurashi, Hesham H. Altowairqi, Samir Samaha, Mohmmad El-Hossary, Dalia |
author_sort | Hawsawi, Nahed Mohammed |
collection | PubMed |
description | Hepatitis C virus (HCV) chronic infection is a major causative factor for several chronic liver diseases, including liver cirrhosis, liver cell failure, and hepatocellular carcinoma. The HCV has seven major genotypes. Genotype 4 is the most prevalent genotype in the Middle East, including Saudi Arabia, followed by genotype 1. The HCV genotype affects the response to different HCV treatments and the progression of liver disease. Currently, combinations of direct-acting antiviral drugs (DAAs) approved for the treatment of HCV achieve high cure rates with minimal adverse effects. Because real-world data from Saudi Arabia about the efficacy of DAAs are still limited, this study was conducted to assess the effectiveness of DAAs in treating patients with chronic hepatitis C and to identify the variables related to a sustained virologic response (SVR) in a real-world setting in Saudi Arabia. This prospective cohort study included 200 Saudi patients with chronic HCV who were 18 years of age or older and had been treated with DAAs at King Abdul-Aziz Specialized Hospital in Taif, Saudi Arabia, between September 2018 and March 2021. The response to treatment was assessed by whether or not an SVR had been achieved at week 12 post treatment (SVR12). An SVR12 was reached in 97.5% of patients. SVR12 rates were comparable for patients of different ages, between men and women, and between patients with and without cirrhosis. In addition, the SVR12 rates did not differ according to the infecting HCV genotype. In this study, the presence of cirrhosis and the patient’s gender were independent predictors of who would not reach an SVR12 (known here as the non-SVR12 group) according to the results of univariate and multivariate binary logistic regression analyses based on the determinants of SVR12. In this population of patients with chronic HCV infection, all DAA regimens achieved very high SVR12 rates. The patients’ gender and the presence of cirrhosis were independent factors of a poor response. |
format | Online Article Text |
id | pubmed-9967136 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99671362023-02-26 Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital Hawsawi, Nahed Mohammed Saber, Tamer Salama, Hussein M. Fouad, Walaa S. Hagag, Howaida M. Alhuthali, Hayaa M. Eed, Emad M. Saber, Taisir Ismail, Khadiga A. Al Qurashi, Hesham H. Altowairqi, Samir Samaha, Mohmmad El-Hossary, Dalia Trop Med Infect Dis Article Hepatitis C virus (HCV) chronic infection is a major causative factor for several chronic liver diseases, including liver cirrhosis, liver cell failure, and hepatocellular carcinoma. The HCV has seven major genotypes. Genotype 4 is the most prevalent genotype in the Middle East, including Saudi Arabia, followed by genotype 1. The HCV genotype affects the response to different HCV treatments and the progression of liver disease. Currently, combinations of direct-acting antiviral drugs (DAAs) approved for the treatment of HCV achieve high cure rates with minimal adverse effects. Because real-world data from Saudi Arabia about the efficacy of DAAs are still limited, this study was conducted to assess the effectiveness of DAAs in treating patients with chronic hepatitis C and to identify the variables related to a sustained virologic response (SVR) in a real-world setting in Saudi Arabia. This prospective cohort study included 200 Saudi patients with chronic HCV who were 18 years of age or older and had been treated with DAAs at King Abdul-Aziz Specialized Hospital in Taif, Saudi Arabia, between September 2018 and March 2021. The response to treatment was assessed by whether or not an SVR had been achieved at week 12 post treatment (SVR12). An SVR12 was reached in 97.5% of patients. SVR12 rates were comparable for patients of different ages, between men and women, and between patients with and without cirrhosis. In addition, the SVR12 rates did not differ according to the infecting HCV genotype. In this study, the presence of cirrhosis and the patient’s gender were independent predictors of who would not reach an SVR12 (known here as the non-SVR12 group) according to the results of univariate and multivariate binary logistic regression analyses based on the determinants of SVR12. In this population of patients with chronic HCV infection, all DAA regimens achieved very high SVR12 rates. The patients’ gender and the presence of cirrhosis were independent factors of a poor response. MDPI 2023-01-30 /pmc/articles/PMC9967136/ /pubmed/36828508 http://dx.doi.org/10.3390/tropicalmed8020092 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hawsawi, Nahed Mohammed Saber, Tamer Salama, Hussein M. Fouad, Walaa S. Hagag, Howaida M. Alhuthali, Hayaa M. Eed, Emad M. Saber, Taisir Ismail, Khadiga A. Al Qurashi, Hesham H. Altowairqi, Samir Samaha, Mohmmad El-Hossary, Dalia Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital |
title | Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital |
title_full | Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital |
title_fullStr | Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital |
title_full_unstemmed | Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital |
title_short | Genotypes of Hepatitis C Virus and Efficacy of Direct-Acting Antiviral Drugs among Chronic Hepatitis C Patients in a Tertiary Care Hospital |
title_sort | genotypes of hepatitis c virus and efficacy of direct-acting antiviral drugs among chronic hepatitis c patients in a tertiary care hospital |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967136/ https://www.ncbi.nlm.nih.gov/pubmed/36828508 http://dx.doi.org/10.3390/tropicalmed8020092 |
work_keys_str_mv | AT hawsawinahedmohammed genotypesofhepatitiscvirusandefficacyofdirectactingantiviraldrugsamongchronichepatitiscpatientsinatertiarycarehospital AT sabertamer genotypesofhepatitiscvirusandefficacyofdirectactingantiviraldrugsamongchronichepatitiscpatientsinatertiarycarehospital AT salamahusseinm genotypesofhepatitiscvirusandefficacyofdirectactingantiviraldrugsamongchronichepatitiscpatientsinatertiarycarehospital AT fouadwalaas genotypesofhepatitiscvirusandefficacyofdirectactingantiviraldrugsamongchronichepatitiscpatientsinatertiarycarehospital AT hagaghowaidam genotypesofhepatitiscvirusandefficacyofdirectactingantiviraldrugsamongchronichepatitiscpatientsinatertiarycarehospital AT alhuthalihayaam genotypesofhepatitiscvirusandefficacyofdirectactingantiviraldrugsamongchronichepatitiscpatientsinatertiarycarehospital AT eedemadm genotypesofhepatitiscvirusandefficacyofdirectactingantiviraldrugsamongchronichepatitiscpatientsinatertiarycarehospital AT sabertaisir genotypesofhepatitiscvirusandefficacyofdirectactingantiviraldrugsamongchronichepatitiscpatientsinatertiarycarehospital AT ismailkhadigaa genotypesofhepatitiscvirusandefficacyofdirectactingantiviraldrugsamongchronichepatitiscpatientsinatertiarycarehospital AT alqurashiheshamh genotypesofhepatitiscvirusandefficacyofdirectactingantiviraldrugsamongchronichepatitiscpatientsinatertiarycarehospital AT altowairqisamir genotypesofhepatitiscvirusandefficacyofdirectactingantiviraldrugsamongchronichepatitiscpatientsinatertiarycarehospital AT samahamohmmad genotypesofhepatitiscvirusandefficacyofdirectactingantiviraldrugsamongchronichepatitiscpatientsinatertiarycarehospital AT elhossarydalia genotypesofhepatitiscvirusandefficacyofdirectactingantiviraldrugsamongchronichepatitiscpatientsinatertiarycarehospital |